GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (NAS:BCTX) » Definitions » PB Ratio

BCTX (BriaCell Therapeutics) PB Ratio : 3.34 (As of Mar. 25, 2025)


View and export this data going back to . Start your Free Trial

What is BriaCell Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-03-25), BriaCell Therapeutics's share price is $4.09. BriaCell Therapeutics's Book Value per Share for the quarter that ended in Jan. 2025 was $1.22. Hence, BriaCell Therapeutics's PB Ratio of today is 3.34.

The historical rank and industry rank for BriaCell Therapeutics's PB Ratio or its related term are showing as below:

BCTX' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 50.84
Current: 3.35

During the past 13 years, BriaCell Therapeutics's highest PB Ratio was 50.84. The lowest was 0.00. And the median was 0.00.

BCTX's PB Ratio is ranked worse than
65.94% of 1283 companies
in the Biotechnology industry
Industry Median: 2.38 vs BCTX: 3.35

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of BriaCell Therapeutics was 64.10% per year. The lowest was -72.30% per year. And the median was -1.30% per year.

Back to Basics: PB Ratio


BriaCell Therapeutics PB Ratio Historical Data

The historical data trend for BriaCell Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics PB Ratio Chart

BriaCell Therapeutics Annual Data
Trend Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 2.80 9.77 - -

BriaCell Therapeutics Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 7.28 4.10

Competitive Comparison of BriaCell Therapeutics's PB Ratio

For the Biotechnology subindustry, BriaCell Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BriaCell Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's PB Ratio falls into.



BriaCell Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

BriaCell Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Jan. 2025)
=4.09/1.223
=3.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


BriaCell Therapeutics  (NAS:BCTX) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


BriaCell Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BriaCell Therapeutics Business Description

Traded in Other Exchanges
Address
235-15th Street, Suite 300, 3rd Floor, Bellevue Centre, West Vancouver, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
Executives
Marc Lustig director 4177 ROCKRIDGE ROAD, WEST VANCOUVER A1 V7W 1A3
Jamieson Bondarenko director 402-1 SCOTT ST.`, TORONTO A6 M5E 1A1
Jane A Gross director 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Rebecca Taub director 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Gadi Levin officer: CFO & Secretary MOSHAV AZRIEL 108, LEV HASHARON L3 4582500
Priore Giuseppe Del officer: Chief Medical Officer 44 WALL STREET, 12TH FLOOR, NEW YORK NY 10005
Williams V. Williams director, officer: President & CEO 620 SOUTH EAGLE ROAD, HAVERTOWN PA 19083
Martin E. Schmieg director 201 S. 25TH STREET, APT. #521, PHILADELPHIA PA 19103
Miguel A. Lopez-lago officer: Chief Scientific Officer 2401 PENNSYLVANIA AVE., APT #12A6, PHILADELPHIA PA 19130
Vaughn C. Embro-pantalony director P.O. BOX 58, 285 SUNSET BLVD, THORNBURY A6 N0H 2P0